Osiris to Present New Clinical and Scientific Data at Desert Foot 2015

Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, will present recent clinical and scientific findings for Grafix®, Stravix™ and TruSkin™, at the 12th Annual 2015 Desert Foot Conference in Phoenix, Arizona on November 18-20, 2015.

“We appreciate the on-going high quality medical education offered during the 2015 Desert Foot conference, which is widely attended by healthcare practitioners who provide care to our U.S. veterans,” said Frank Czworka, Vice President and GM Wound care. “The management of complex, chronic wounds continues to be challenging for patients and their healthcare practitioners. We will be presenting data demonstrating how Grafix has been used successfully to treat challenging wounds and look forward to sharing scientific findings supporting our wound care technologies at the meeting.”

Presentations include:

• Introduction of a Viable Intact Cryopreserved Placental Membrane to Expedite Wound Closure and Reduce the Number of Ulcer Related Visits in the VA Healthcare System
• Atypical Ulcerating Skin Disease: Treating Refractory Lower Extremity Wounds with a Viable Intact Cryopreserved Placental Membrane
• Efficient Wound Closure Using a Viable Cryopreserved Placental Tissue and Negative Pressure Therapy in a Non-compliant Patient with Neuropathic Diabetic Foot Ulcer
• The Efficacy of a Cryopreserved Placental Membrane When Used as Part of a Dual-Protocol Algorithm in Complex Ulcer Patients
• Treatment of Pyoderma Gangrenosum with a Cryopreserved Placental Membrane
• Post-operative Limb Salvage Using a Cryopreserved Human Amniotic Membrane
• Surgical Use of Cryopreserved Viable Placental Membranes (CVPM) for Low Extremity Wounds
• Characterization of a Novel Cryopreserved Placental Allograft for Surgical Procedures
• Development of a Novel Viable Cryopreserved Skin Allograft (vCSA)
• Characterization of a Novel Viable Cryopreserved Skin Allograft (vCSA)

Osiris Events include:

About Osiris Therapeutics

Osiris Therapeutics, Inc., based in Columbia, Maryland, a leader in researching, developing and marketing cellular regenerative medicine products that improve the health and lives of patients and lower overall healthcare costs. Having developed the world’s first approved stem cell drug, Osiris works to further advance the medical field. Osiris’ research and development in biotechnology focuses on innovation in regenerative medicine – including bioengineering, stem cell research and viable tissue based products. Osiris has achieved commercial success with products in orthopaedics, sports medicine and wound care, including BIO4 ®, a viable bone matrix, Cartiform®, a viable osteochondral allograft, Grafix, a cryopreserved placental membrane, TruSkin, a viable human skin allograft and Stravix, a durable placental allograft.

Osiris, Grafix and Cartiform are registered trademarks of Osiris Therapeutics, Inc.; TruSkin and Stravix are trademarks of Osiris Therapeutics, Inc. BIO4 is a registered trademark of Stryker Corporation (NYSE: SYK). More information can be found on the company's website, www.Osiris.com. (OSIR-G)

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements include statements about our expectations, beliefs, plans, objectives, intentions, assumptions and other statements that are not historical facts. Words or phrases such as "anticipate," "believe," "continue," "ongoing," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project" or similar words or phrases, or the negatives of those words or phrases, may identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. Examples of forward-looking statements may include, without limitation, statements regarding any of the following: our product development efforts; our clinical trials and anticipated regulatory requirements, and our ability to successfully navigate these requirements; the success of our product candidates in development; status of the regulatory process for our biologic drug candidates; implementation of our corporate strategy; our financial performance; our product research and development activities and projected expenditures, including our anticipated timeline and clinical strategy biologic drug candidates and marketed Biosurgery products (including Grafix, BIO4, Cartiform, TruSkin and Stravix); our cash needs; patents, trademarks and other proprietary rights; the safety and ability of our products and potential products to treat disease; our ability to supply a sufficient amount of our marketed products or product candidates and, if approved or otherwise commercially available, products to meet demand; our costs to comply with governmental regulations; our plans for sales and marketing; our plans regarding facilities; types of regulatory frameworks we expect will be applicable to our products and potential products; and results of our scientific research. Forward-looking statements are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. Our actual results could differ materially from those anticipated in forward-looking statements for many reasons, including the factors described in the section entitled "Risk Factors" in our Annual Report on Form 10-K and other Periodic Reports filed on Form 10-Q, with the United States Securities and Exchange Commission. Accordingly, you should not unduly rely on these forward-looking statements. We undertake no obligation to publicly revise any forward-looking statement to reflect circumstances or events after the date of this press release or to reflect the occurrence of unanticipated events.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151118005662/en/